Wellington Management Group LLP Sells 7,771 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Wellington Management Group LLP decreased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 0.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,815,558 shares of the company’s stock after selling 7,771 shares during the quarter. Wellington Management Group LLP owned approximately 8.12% of Kymera Therapeutics worth $122,604,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in KYMR. Swiss National Bank grew its stake in shares of Kymera Therapeutics by 19.7% in the 3rd quarter. Swiss National Bank now owns 79,100 shares of the company’s stock worth $1,099,000 after acquiring an additional 13,000 shares in the last quarter. FMR LLC grew its position in Kymera Therapeutics by 3.9% during the third quarter. FMR LLC now owns 870,547 shares of the company’s stock valued at $12,101,000 after buying an additional 32,335 shares during the period. Hsbc Holdings PLC bought a new position in Kymera Therapeutics during the third quarter valued at about $185,000. Dark Forest Capital Management LP grew its position in Kymera Therapeutics by 89.0% during the third quarter. Dark Forest Capital Management LP now owns 36,698 shares of the company’s stock valued at $510,000 after buying an additional 17,280 shares during the period. Finally, Algert Global LLC grew its position in Kymera Therapeutics by 130.6% during the third quarter. Algert Global LLC now owns 128,532 shares of the company’s stock valued at $1,787,000 after buying an additional 72,802 shares during the period.

Insider Transactions at Kymera Therapeutics

In other news, Director Bruce Booth sold 16,740 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total value of $593,433.00. Following the sale, the director now directly owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Bruce Booth sold 16,740 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total value of $593,433.00. Following the sale, the director now directly owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joanna Horobin sold 8,500 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Trading Up 0.2 %

Shares of Kymera Therapeutics stock opened at $31.27 on Friday. Kymera Therapeutics, Inc. has a 12-month low of $9.60 and a 12-month high of $45.31. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -12.46 and a beta of 2.25. The company’s 50-day moving average price is $34.69 and its 200-day moving average price is $33.80.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The firm had revenue of $10.30 million for the quarter, compared to the consensus estimate of $14.24 million. During the same period in the prior year, the firm posted ($0.70) earnings per share. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on KYMR shares. HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of Kymera Therapeutics in a research report on Monday. Piper Sandler increased their price target on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. increased their price target on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Oppenheimer reduced their price target on shares of Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. Finally, Truist Financial upped their price objective on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a report on Friday, March 1st. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.70.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.